Endpoints NewsOriginal article
#ESC26: AstraZeneca's relaxin pill shows promise in mid-stage heart failure trial
Phase 2Mixedoral relaxin agonistPositive
AI Analysis
Summary
AstraZeneca's oral relaxin agonist demonstrated partial efficacy in a mid-stage heart failure trial, improving cardiac function in some but not all patients. The mixed results represent a modest positive outcome for the program.
Clinical Trial Data
Phase
2
Outcome Details
improved cardiac function in some, though not all, patients
Importance:6/10
Sentiment:
0.35
Phase 2 dataheart failureoral formulationpartial successESC 2026
Related Companies
Read the original article
Published by Endpoints News on August 30, 2026 7:19 AM